Rapid communication: Protective effect of a nuclear factor κB inhibitor, pyrolidium dithiocarbamate, in the kidney of rats with nephrolithiasis induced by ethylene glycol

Journal of Endourology

Volumn 21, Issue 9, 2007, Pages 1097-1106

  Tugcu, Volkan ^a,e   Ozbek, Emin ^b   Kemahli, Eray ^a   Cekmen, Mustafa Baki ^c   Caner, Nazli ^d   Somay, Adnan ^b   Erturkuner, Pelin ^d   Seckin, Ismail ^d   Demir, Cennet Gural ^c   Altug, Tuncay ^d   Tasci, Ali Ihsan ^a  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b VAKIF GUREBA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYLENE GLYCOL; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; NITRIC OXIDE; PYRROLIDINE DITHIOCARBAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; ENZYME ACTIVITY; HYPEROXALURIA; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE; MALE; NEPHROLITHIASIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CRYSTALLIZATION; ETHYLENE GLYCOL; GLUTATHIONE; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TUBULES; MALE; MALONDIALDEHYDE; MICROSCOPY, ELECTRON, TRANSMISSION; NEPHROLITHIASIS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; THIOCARBAMATES;

EID: 35348965222     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2007.0074     Document Type: Article

References (33)

1. Khan SR. Animal models of kidney stone formation: An analysis. World J Urol 1997;15:236-243.
2. Hodgkinson A. Oxalic acid in biology and medicine. Clin Chim Acta 2005;354:159-66.
3. Pragasam V, Kalaiselvi P, Sumitra K, Srinivasan S, Varalakshmi P. Counteraction of oxalate induced nitrosative stress by supplementation of L-arginine, a potent antilithic agent. Clin Chim Acta 2005;354:159-166.
4. Thamilselvan S, Hackett RL, Khan SR. Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J Urol 1997;157:1059-1063
5. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994;269:4705-4708
6. Gilad E, Wong HR, Zingarelli B, et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: Role of inhibition of NFκB activation. FASEB J 1998;12:685-693.
7. Chatterjee PK, Patel NS, Kvale EO, et al. Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int 2002;61:862-871.
8. Goligorsky MS, Brodsky SV, Noiri E. Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int 2002;61:855-861.
9. Fischer PA, Dominguez GN, Cuniberti LA, et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: Is nitric oxide involved ? J Am Soc Nephrol 2003;14:653-660.
10. Montilla P, Cruz A, Padillo FJ, Tunez I, et al. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res 2001;31:138-144.
11. Paul JL, Sall ND, Soni T. et al. Lipid peroxidation abnormalities in hemodialyzed patients. Nephron 1993;64:106-109.
12. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 1992;175:1181-1194.
13. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 1999;17:99-106.
14. Elman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
15. Houghton DC, Plamp CE, DeFehr JM, Bennett WM, Porter G, Gilbert D. Gentamicin and tobramicin nephrotoxicity: A morphologic and functional comparison in the rat. Am J Pathol 1978;93:137-152
16. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-310.
17. Khan SR, Shevock PN, Hackett RL. Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis. J Urol 1992;147:226-230.
18. Itoh Y, Yasui T, Okada A, et al. Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis. J Urol 2005;173:271-275.
19. Halliwell B, Grootveld M. The measurement of free radical reactions in humans: Some thoughts for future experimentation. FEBS Lett 1987;213:9-14.
20. Chen WC, Chen HY, Wu HC, et al. Vascular endothelial growth factor gene polymorphism is associated with calcium oxalate stone disease. Urol Res 2003;31:218-222.
21. Esen T, Akinci M, Aytekin Y, Altug T, Hekim N. The effects of citrate, polyphosphates and pridoxin on intratubular crystallization in hyperoxaluric rats. Turkish J Urol 1990;16:365-370.
22. Selvam R. Calcium oxalate stone disease: Role of lipid peroxidation and antioxidants. Urol Res 2002;30:35-47.
23. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-372.
24. Thamilselvan S, Menon M. Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status. BJU Int 2005;96:117-126.
25. Tugcu V, Ozbek E, Tasci AI, Kemahli E, et al. Selective nuclear factor kappa-B inhibitors, pyrolidium dithiocarbamate and sulfasalazine, prevent the nephrotoxicity induced by gentamicin. BJU Int 2006;98:680-686.
26. Zhang F, Siow YL, O K. Hyperhomocysteinemia activates NF-kappaB and inducible nitric oxide synthase in the kidney. Kidney Int 2004;65:1327-1338.
27. Leung JC, Marphis T, Craver RD, et al. Altered NMDA receptor expression in renal toxicity: Protection with a receptor antagonist. Kidney Int 2004;66:167-176.
28. Nakashima O, Terada Y, Inoshita S, Kuwahara M, Sasaki S, Marumo F. Inducible nitric oxide synthase can be induced in the absence of active nuclear factor-kappaB in rat mesangial cells: Involvement of the Janus kinase 2 signaling pathway. J Am Soc Nephrol 1999;10:721-729.
29. Jang J, Park EY, Seo SI, Hwang TK, Kim JC. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 2006;98:435-439.
30. Holmes RP, Assimos DG. The impact of dietary oxalate on kidney stone formation. Urol Res 2004;32:311-316.
31. Pais VM Jr, Holmes RP, Assimos DG. Effect of dietary control of urinary uric acid excretion in calcium oxalate stone formers and non-stone-forming controls. J Endourol 2007;21:232-235.
32. Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 2005;33:65-69.
33. Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 2003;62:1123-1128.